Donga-ST and Kwangdong Pharmaceutical jointly held a ceremony to promote Contrave, a weight loss medicine made by Orexigen Therapeutics, Donga-ST said Friday.
Contrave, sold by Kwangdong in Korea since 2016, is a FDA-approved weight-loss medication working on two areas of the brain—the hunger center and the reward system—to reduce hunger and help control cravings.
Donga-ST 동아ST signed a contract with Kwangdong 광동제약 in August to jointly sell the medicine.
The two companies will start sales and marketing of Contrave for general hospitals from Sep. 1.
The ceremony was attended by Donga-ST CEO Min Jang-sung 민장성, Kwangdong Vice President Ki Young-duk 기영덕 and officials of the two companies.
The event aimed to strengthen cooperation between the two firms and to set sales goals before the launch of co-promotion activities. It also included lectures on obesity-related diseases, and marketing.
Contrave topped the market share in North America with sales of about $127 million in 2016, thanks to strong efficacy and safety with long-term prescription for non-aromatized medicines.
Korea’s obesity treatment market is estimated to be about 90 billion won ($79 million), with the prevalence of obesity steadily increasing.
“We hope to create synergy between the two companies based on the systematic cooperation,” a Donga-ST official said. “We will grow Contrave into a blockbuster product based on the company’s know-how accumulated over excellent sales force in chronic disease treatment products.
<© Korea Biomedical Review, All rights reserved.>